Objective:To investigate psychological needs, state of mind and psychological feeling, and analyze the related factors.Method:2000 subjects over 60 years of age in Beijing are evaluated with the part of psychological needs of the Life State Inventory for Residents of Beijing.Results:The intergeneration relationship, state of mind and psychological feeling of the elderly were well. They were related each other closely. The state of mind improved with educational level and that of male were better than female. Most of the elderly considered that the effect of the state of mind on the quality of life was obvious. The psychological feeling declined with aged and improved with educational level. The satisfaction degree of economy and care, filial obedience, health were related to life satisfaction degree, state mind and psychological feeling.Conclusion:Psychological needs of the elderly were satisfied in general. The state of mind was one of the important factors on the quality of life.

Objective To observe the effect of Lisui Decoction in treating low-risk type myelodysplastic syndrome (MDS).Methods 79 such cases were randomly divided into a group treatment group with 45 cases and a control group with 34 cases.The treatment group Was treated wim Lisui Decoction and the control group was treated with Stanozolol RAS and vitamin B6.Such indexes as clinical curative effects,peripheral blood,and changes of T cell phenotypic subpopulations and medulla picture were observed.Results There was between the treatment group and the control group.The CR rate was 8.57%and 2.94%.and the total effective rate was 71.1%and 38.2%in the treatment group and the control group respectively,showing significant difierence.The peripheral blood.T cell phenotypic subpopulations and the dysplastic hematopoiesis in erythroid also showed significant difiefences.Conclusion Lisui Decoction can improve hematopoiesis of bone marrow and it is effective in treating low-risk type myelodysplastic syndrome.

Objective To explore the prognostic factors of brain metastases from primary breast cancer treated with stereotactic radiotherapy (SRT).Methods Retrospectively analyze 37 brain metastatic patients from primary breast cancer.Among these patients nineteen were treated with stereotactic radiotherapy alone,eight patients were treated with whole brain radiotherapy (WBRT) plus SRT,the other ten patients were intracranial recurrence after WBRT and treated with SRT for salvage.Kaplan-Meier analyses were used to calculate survival time.Logrank and Cox proportional hazards regression analyses were performed for univariate and multivariate analyses.Results The median follow-up time were 11 months and 15 months for the whole group and the alive.The median overall survival time was 11 months (95％ CI =6-16.month) for the whole group.The median overall survival time was 13.5 months for the whole group.In univariate analysis,the triple negative breast cancer (x2 =5.95,P =0.004),lower Karnofsky performance score (KPS,x2 =13.85,P =0.000),the interval between the diagnosis of the primary tumor and brain metastases ≤ 30 months (x2 =6.62,P =0.010),high RPA grade (x2 =15.35,P =0.000) and intracranial recurrence after whole brain radiotherapy (x2 =4.43,P =0.035) were negative prognostic factors for brain metastasis of breast cancer treated with stereotactic radiotherapy.In multivariate analyses,the triple negative breast cancer (x2 =9.58,P =0.008),lower KPS (x2 =6.65,P =0.010),and intracranial recurrence after whole brain radiotherapy (x2 =3.95,P =0.047) were negative prognostic factor.Conclusion The triple negative breast cancer,lower KPS,and intracranial recurrence after WBRT were negative prognostic factor for brain metastasis from primary breast cancer treated with SRT.

In previous studies, we demonstrated 10 types of lymphocytes in lymph nodes, each exhibited a different fluorescent color by our thioflavine staining method. Among them, 4 types were able to differentiate into plasma cells of the same fluorescent colors. In the present study, different types of lymphocytes were demonstrated in human peripheral blood by their different fluorescent colors after thioflavine staining. The lymphocytes from the venous blood of 50 healthy persons were isolated with Ficoll-Conray solution and E-rosette and EAC-rosette tests and fluorescent staining with thioflavine were performed. Most of the lymphocytes in peripheral blood are small ones with nuclei and cytoplasm showing blue fluorescence and the blue fluorescence of the cytoplasm is paler than that of the nuclei. The nuclei in a part of these lymphocytes have distinct boundaries. The nuclei in another part of these lymphocytes are smaller and with indistinct boundaries and indentation on one side and show dim fluorescence. Other lymphocytes show different fluorescence. Some show blue round nuclei with distinct nuclear membrane, and no color of fluorescence in cytoplasm, but with blue white patches on one side of the nuclei. Some show dark blue nuclei and bright blue cytoplasm and others show orange yellow or orange red nuclei and yellow cytoplasm. In addition, lymphocytes of grayish blue or grayish yellow nuclei and bluish green cytoplasm or lymphocytes of yellowish fluorescence may be seen at times. Very few lymphoeytes of orange red nuclei with nearly no cytoplasm may be seen occasionally.The lymphocytes with blue fluorescence and indentation on one side of nucleus, those with blue nuclei and blue white patches in the cytoplasm as well as those with orange yellow nuclei and yellow cytoplasm can form E-rosettes with sheep erythrocytes. They are T cells. The lymphocytes with distinct boundaries of nucleus, small size and blue fluorescence those with dark blue nuclei and bright blue cytoplasm as well as those with orange red nuclei and yellow cytoplasm can form EAC-rosettes with sheep erythrocytes sensitized by specific antibody and complement. They are B cells. The lymphocytes with blue nuclei and blue white patches may transform into lymphocytes with orange yellow nuclei and yellow cytoplasm under ultra-violet light irradiation. The latter are few in number in the blood but may be progressively increased in number on prolonged observation. They belong to Group Ⅲ of lymphocytes and are mainly located in the paracortical thymus-dependent zone of lymph nodes. The sma ller lymphocytes with blue fluorescence and distinct nuclear boundary may transform into lymphocytes with orange red nuclei and yellow cytoplasm, which are also very few in number in the blood and are also progressively increased in number on prolonged observation. They belong to Group Ⅱ of lymphocytes and constitute the main component of lymph nodules in lymph nodes.

BACKGROUND:Glial scar and cavity formation fol owing spinal cord injury inhibits axonal entrance, so limited axonal regeneration, less secretion of neurotrophic factor and inhibitors in the microenvironment of axonal growth are considered as major impediments for impacting functional recovery of patients with spinal cord injury.
OBJECTIVE:To analyze literatures home and abroad related to the biological characters of astrocytes and glial scar hyperplasia after spinal cord injury, and to provide a theoretical basis for the mechanism underlying glial scar formation fol owing spinal cord injury.
METHODS:PubMed and Wanfang databases were retrieved using the keywords“astrocytes, reactive astrogliosis, glial scar, spinal cord injury”in English and Chinese, respectively. Final y 62 literatures were selected for overview.
RESULTS AND CONCLUSION:Currently, studies concerning the biological characters of astrocytes, reactive astrogliosis and glial scar formation fol owing spinal cord injury have achieved some progresses. Studies mainly focus on the sole impediment for spinal cord injury, and treatment also aims at inhibiting single factor, but interactions among factors have not been confimed. In addition, the regulatary mechanisms of specific intracel ular and extracel ular signal molecule in the astrocytes, and effective control and interference of glial scar formation fol owing spinal cord injury stil need in-depth study.

AIM: To study the role and regulation of calcineurin(CaN) in angiotensin II(AngⅡ)-stimulated cardiacmyocyte hypertrophy of rats. METHODS: Using AngⅡ to induce the cultured cardiac myocyte hypertrophy of rats, and investigating the effect of CaN inhibitor on [ 3H]-leucine incorporation of AngⅡ-stimulated cardiomyocytes and the regulation of various factors on CaN activity in cardiomyocytes.RESULTS: AngⅡ can stimulate the CaN activity in cultured neonatal rat cardiomyocytes in a dose- and time-dependent manner. In cardiac myocytes incubated with 10, 100, 1000 nmol?L -1 of AngⅡ for 12h, the CaN activities increased respectively by 13%,57%( P

AIM: To observe the changes of metallothionein (MT) in various tissues of mice during hyperhomocysteinemia. METHODS: Intraperitoneal injection of homocysteine into mice induced hyperhomocysteinemia. The contents of tissue MT and malondialdehyde (MDA) in liver, heart and kidney were determined. RESULTS: Compared with control group, tissue MT levels in Hcy-group animals were increased by 210% ( P 0.05),respectively, compared with Hcy alone group. Tissue MDA contents were decreased by 24% ( P

Objective To investigate the influence of endorectal balloon on normal tissue dosimetry in prostate cancer patients treated with intensity-modulated radiation therapy (IMRT). Methods Ten patients with prostate cancer were included and each had two sets of planning CT-scans:one with and one without an air-filled endorectal balloon. Target volumes and organs at risk ( rectum, bladder,femoral heads)were contoured on the 20 CT scans and IMRT plannings were performed. The prescription dose was 78 Gy to 95％ of planning target volume. The percentage of volume of organs at risk ( without or with endorectal balloon) receiving more than 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, 60 Gy, 70 Gy and 75 Cy (V10 - V70 ,in increments of 10 Gy, and V75 ) were analyzed. Results The V1o - V60 0f rectum with endorectal balloon were 75. 5％ , 52. 6％ , 35. 3％ , 26. 1％, 19. 6％ , 14. 2％ , and those without endorectal balloon were 82. 2％ , 62. 8％ , 43. 9％ , 31. 4％ , 24. 0％ , 17. 1％ , respectively ( X2 = g. 46, P< 0. 01 ). Use of endorectal balloon significantly reduced the dose to the rectum ( v10 - V60 ) . The V70 and V75 of rectum with endorectal balloon were 9. 1％ and 8. 2％; and those without endorectal balloon were 9. 9％ and 6. 2％ respectively ( X2 = 1. 82,P＞0. 05) . The difference was not significant. There were no significant differences in the dose to bladder,left and right femoral head between patients with and without endorectal balloon.Conclusions Endorectal balloon can significantly decrease the medium and low dose volume of rectum for prostate cancer patients treated with IMRT, which may reduce the rectal toxicity.

Objective To evaluate the value of radiotherapy following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone ( R?CHOP )?based chemotherapy for patients with early?stage Waldeyer’ s ring diffuse large B?cell lymphoma ( WR?DLBCL). Methods Eighty?three patients diagnosed with early?stage WR?DLBCL who were admitted to our hospital from 2000 to 2013 were enrolled in the study. In these patients, twenty?five had stageⅠdisease and fifty?eight had stageⅡdisease. All patients received R?CHOP?based chemotherapy with ( n= 62 ) or without ( n= 21 ) involved?field radiotherapy ( Waldeyer’ s ring plus cervical lymph nodes ) . The overall survival ( OS ) , progression?free survival ( PFS) , and local?regional control ( LRC) rates were calculated using the Kaplan?Meier method. The univariate analysis was performed using the log?rank method. The multivariate analysis was performed using the Cox regression model. Results In all patients, the 5?year sample size was 18;the 5?year OS, PFS, and LRC rates were 89%, 84%, and 90%, respectively. According to the univariate analysis, patient age greater than 60 years, an increased lactate dehydrogenase level, Eastern Cooperative Oncology Group ( ECOG ) performance status no less than 2, and International Prognostic Index ( IPI ) no less than 2 were poor prognostic factors. Patient age greater than 60 years, a tumor size no less than 5 cm, ECOG performance status no less than 2, and IPI no less than 2 were influencing factors for PFS and LRC rates. In addition to the treatment with rituximab, patients treated with consolidative radiotherapy had significantly higher PFS and LRC rates (94% vs. 58%, P=0?003;100% vs. 61%, P=0?000) as well as slightly higher OS rate ( 9 4%vs . 7 1%, P=0?0 6 3 ) than those treated without radiotherapy . Conclusions Consolidative radiotherapy following R?CHOP?based chemotherapy significantly improves PFS, LRC, and probably OS rates for early?stage WR?DLBCL. This conclusion still needs to be confirmed by prospective studies with a large sample size.

Objective To evaluate the clinical features, treatment outcome, and prognostic factors in patients with primary Waldeyer’ s ring diffuse large B?cell lymphoma (WR?DLBCL). Methods This study included 200 patients with a confirmed diagnosis of primary WR?DLBCL admitted to our hospital from 2000 to 2013, who consisted of 50 stage I patients, 125 stage II patients, and 25 stage III?IV patients. Most patients received 4?6 cycles of CHOP or CHOP?based chemotherapy with or without involved field radiotherapy (Waldeyer′s ring+cervical lymph node region). Results The 5?year sample size was 71. The 5?year overall survival (OS), progression?free survival (PFS), and locoregional control (LRC) rates for the whole group were 78%, 72%, and 87%, respectively. In the 175 early stage patients, chemoradiotherapy resulted in significantly higher OS, PFS, and LRC than chemotherapy alone (86% vs. 70%, P= 0?? 001;84% vs. 58%, P= 0?? 000;97% vs. 66%, P= 0?? 000). Univariate analysis showed that age, tumor size, stage, lactate dehydrogenase level, and International Prognostic Index were prognostic factors for OS, PFS, and LRC ( P= 0?? 000?0?? 036), while the prognostic factors for PFS also included Eastern Cooperative Oncology Group score and cervical nodal involvement (P= 0?? 018). Multivariate analysis showed that age and stage were prognostic factors for OS and LRC (P= 0?? 003?0?? 022), and age was the prognostic factor for PFS (P= 0?? 000). Conclusions WR?DLBCL has distinct clinical features and favorable prognoses. For early stage patients, combined?modality therapy results in significantly higher OS, PFS, and LRC.